Intelligent Bio Solutions (Nasdaq: INBS) hits cybersecurity milestone for 510(k)
Rhea-AI Filing Summary
Intelligent Bio Solutions Inc. reports that it has addressed all cybersecurity and software-related review items for its planned FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System. This follows independent third-party penetration testing, with 100% of medium-risk vulnerabilities remediated and low-risk items reduced from 11 to 2, supported by risk-based justifications that remaining issues do not affect device safety, effectiveness, or performance.
The company has also fully resolved all 19 software bill of materials (SBOM) vulnerabilities, aligning documentation and system configuration with FDA guidance and obtaining independent verification that no issues remain. Management states these steps materially reduce regulatory risk and strengthen its 510(k) package, which is on track for submission in calendar H2 2026, initially targeting codeine detection in a multi-billion-dollar U.S. drug screening market. A manufacturing partnership with Syrma Johari MedTech is expected to deliver more than 40% annual production cost savings and approximately 20 percentage-point gross margin improvement to support a scalable U.S. launch following potential FDA clearance.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
510(k) submission timing: calendar H2 2026
Medium-risk vulnerabilities remediated: 100% of medium-risk vulnerabilities
Low-risk vulnerabilities remaining: Reduced from 11 to 2
+5 more
8 metrics
510(k) submission timing
calendar H2 2026
Planned timing for FDA 510(k) notification submission
Medium-risk vulnerabilities remediated
100% of medium-risk vulnerabilities
All medium-risk cybersecurity issues addressed before 510(k) submission
Low-risk vulnerabilities remaining
Reduced from 11 to 2
Low-risk cybersecurity vulnerabilities after remediation cycle
SBOM vulnerabilities resolved
19 SBOM vulnerabilities
All software bill of materials vulnerabilities fully resolved
Production cost savings
more than 40% annual production cost savings
Expected benefit from Syrma Johari MedTech manufacturing partnership
Gross margin improvement
approximately 20 percentage-point annual gross margin improvement
Expected improvement supporting scalable U.S. launch
Drug detection window
16-24 hours
Recent drug use detection window prior to testing
Result time
under ten minutes
Time for the Intelligent Fingerprinting Drug Screening System to deliver results
Key Terms
FDA 510(k) submission, penetration testing, software bill of materials (SBOM), Forensic Use Only, +1 more
5 terms
FDA 510(k) submission regulatory
"addressed all the cybersecurity and software-related review items for its upcoming FDA 510(k) submission"
An FDA 510(k) submission is a regulatory filing to show a new medical device is sufficiently similar to an already-approved device so it can be marketed in the U.S. without undergoing the most extensive premarket review. For investors, 510(k) clearance is a key milestone that reduces regulatory uncertainty and shortens time to sales—think of it as proving a new product is close enough to an established model to be sold without rebuilding trust from scratch.
penetration testing technical
"follows the Company’s recent completion of independent third-party penetration testing"
Penetration testing is a controlled security check where experts try to break into a company’s computer systems, networks or applications to find weaknesses before real attackers do. For investors it signals how well a company manages cyber risk, potential costs from breaches or compliance failures, and the firmness of operational defenses—think of it as hiring a professional to test all the locks and alarm systems so vulnerabilities can be fixed before they cause damage.
software bill of materials (SBOM) technical
"all 19 software bill of materials (SBOM) vulnerabilities have been fully resolved"
A software bill of materials (SBOM) is a detailed inventory that lists all the pieces, libraries and third‑party code used to build a software product — like an ingredient label for an app. Investors pay attention because SBOMs expose security weaknesses, licensing obligations and maintenance needs that can create unexpected costs, outages or legal risk; having a clear SBOM helps assess operational resilience and the potential future cost of keeping the software safe and compliant.
Forensic Use Only regulatory
"expected to open opportunities for the Company in the U.S. market beyond Forensic Use Only settings"
A label meaning a test, device, or kit is intended only for legal, investigative, or quality-control purposes and not for diagnosing or treating patients. Think of it like a tool stamped “for museum display only” — it may prove something in court or help investigators, but it cannot be used by doctors for medical decisions; that limitation affects who can buy it, how it’s reimbursed, and its commercial value.
gross margin financial
"expected to deliver annual production cost savings of more than 40% and an expected annual gross margin improvement"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What key milestone did Intelligent Bio Solutions (INBS) report on July 23, 2026?
Intelligent Bio Solutions (INBS) reported it has addressed all cybersecurity and software-related review items for its planned FDA 510(k) submission, following independent third-party penetration testing and full remediation of identified vulnerabilities to support its Intelligent Fingerprinting Drug Screening System.
What cybersecurity and SBOM vulnerability progress did INBS disclose?
INBS disclosed that 100% of medium-risk cybersecurity vulnerabilities were remediated, low-risk issues were reduced from 11 to 2, and all 19 software bill of materials (SBOM) vulnerabilities were fully resolved, with independent third-party verification confirming no remaining issues.
When does INBS plan to submit its FDA 510(k) and what is the initial indication?
INBS plans to submit its 510(k) notification in calendar H2 2026, with the initial indication targeting codeine detection. The company believes this submission could open opportunities in the U.S. drug screening market beyond Forensic Use Only settings.
What U.S. market opportunity is Intelligent Bio Solutions (INBS) targeting?
INBS is targeting the multi-billion-dollar U.S. drug screening market, including workplace testing, criminal justice, pain management, law enforcement, and substance abuse treatment, using its Intelligent Fingerprinting Drug Screening System once regulatory clearance is obtained.
What cost and margin benefits are expected from INBS’s Syrma Johari MedTech partnership?
The Syrma Johari MedTech manufacturing partnership is expected to deliver more than 40% annual production cost savings and an approximately 20 percentage-point annual gross margin improvement, supporting a scalable U.S. commercial launch of INBS’s drug screening system after potential FDA clearance.
How does INBS’s Intelligent Fingerprinting Drug Screening System work and how fast are results?
The Intelligent Fingerprinting Drug Screening System collects fingerprint sweat samples in seconds and delivers results in under ten minutes. It is designed to detect recent drug use within about 16–24 hours before testing and is already commercially deployed outside the U.S.